HER2 Testing and the Utility of Ki67
Sunil Verma, MD, MSEd, FRCPC, associate professor, University of Toronto, chair, Breast Medical Oncology, Sunnybrook Odette Cancer Centre, comments on HER2 testing and the utility of Ki67.
Clinical Pearls
- Recent ASCO-CAP guidelines lay out what is considered to be HER2 positive, negative, or equivocal.
- HER2 testing should be done in high volume, well-equipped, quality-assured pathology centers.
- The role for Ki67 as a prognostic marker is well-studied, though significant issues remain regarding its predictive utility and validity.
- These issues must be addressed before Ki67 is used routinely in clinical practice.
Sunil Verma, MD, MSEd, FRCPC, associate professor, University of Toronto, chair, Breast Medical Oncology, Sunnybrook Odette Cancer Centre, comments on HER2 testing and the utility of Ki67.
Related Videos
Related Content
Sequencing Sacituzumab and Other Drugs in HR+, HER2- Breast Cancer
May 16th 2024Article
During a Case-Based Roundtable® event, Stephanie L. Graff, MD, discussed multiple later-line treatment options in hormone receptor–positive breast cancer with participants in the first article of a 2-part series.
Read More
